ATE249832T1 - Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation - Google Patents
Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardationInfo
- Publication number
- ATE249832T1 ATE249832T1 AT96942934T AT96942934T ATE249832T1 AT E249832 T1 ATE249832 T1 AT E249832T1 AT 96942934 T AT96942934 T AT 96942934T AT 96942934 T AT96942934 T AT 96942934T AT E249832 T1 ATE249832 T1 AT E249832T1
- Authority
- AT
- Austria
- Prior art keywords
- olanzapine
- autism
- medication
- salt
- manufacture
- Prior art date
Links
- 208000020706 Autistic disease Diseases 0.000 title abstract 2
- 208000036626 Mental retardation Diseases 0.000 title abstract 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 title abstract 2
- 229960005017 olanzapine Drugs 0.000 title abstract 2
- 206010003805 Autism Diseases 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Chemical Treatment Of Metals (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Luminescent Compositions (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
- Transplanting Machines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1316296P | 1996-03-11 | 1996-03-11 | |
| PCT/US1996/019576 WO1997033585A1 (en) | 1996-03-11 | 1996-12-04 | Method for treating autism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE249832T1 true ATE249832T1 (de) | 2003-10-15 |
Family
ID=21758619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96942934T ATE249832T1 (de) | 1996-03-11 | 1996-12-04 | Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0946179B1 (de) |
| JP (1) | JP2000506860A (de) |
| KR (1) | KR19990087715A (de) |
| CN (1) | CN1213970A (de) |
| AT (1) | ATE249832T1 (de) |
| AU (1) | AU709181B2 (de) |
| BR (1) | BR9612552A (de) |
| CA (1) | CA2248741A1 (de) |
| CZ (1) | CZ290498A3 (de) |
| DE (1) | DE69630055T2 (de) |
| EA (1) | EA000768B1 (de) |
| ES (1) | ES2206614T3 (de) |
| HU (1) | HUP9903688A3 (de) |
| IL (1) | IL126161A0 (de) |
| NO (1) | NO984197L (de) |
| NZ (1) | NZ324615A (de) |
| PL (1) | PL328948A1 (de) |
| TR (1) | TR199801798T2 (de) |
| WO (1) | WO1997033585A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1133299A1 (de) | 1998-11-23 | 2001-09-19 | Sepracor Inc. | 2-hydroxymethylolanzapine enthaltende zusammensetzungen und verfahren |
| CA2351718A1 (en) | 1998-11-23 | 2000-06-02 | Sepracor Inc. | Desmethylolanzapine compositions and methods |
| JP2002530340A (ja) * | 1998-11-23 | 2002-09-17 | セプラコール， インク． | オランザピン−ｎ−オキサイドを含む医薬組成物 |
| CA2879113C (en) | 2012-07-22 | 2021-11-16 | Indiana University Research And Technology Corporation | Modulation sapp, sapp alpha and bdnf levels in individuals diagnosed with fxs and asd |
| RU2696481C2 (ru) | 2013-10-14 | 2019-08-02 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Применение акампросата для модулирования активации erk1/2 в животных моделях fxs и asd и людей с диагностированными fxs и asd |
| RU2666598C1 (ru) * | 2017-07-14 | 2018-09-11 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Средство для коррекции расстройств аутистического спектра |
| KR102285577B1 (ko) | 2020-11-11 | 2021-08-04 | 김의철 | 자폐를 가진 유소년의 무약물 치료방법 및 시스템 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225407A (en) * | 1990-02-22 | 1993-07-06 | Glaxo Group Limited | 5-HT3 receptor antagonists for the treatment of autism |
| US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
-
1996
- 1996-12-04 TR TR1998/01798T patent/TR199801798T2/xx unknown
- 1996-12-04 CZ CZ982904A patent/CZ290498A3/cs unknown
- 1996-12-04 EA EA199800821A patent/EA000768B1/ru not_active IP Right Cessation
- 1996-12-04 CA CA002248741A patent/CA2248741A1/en not_active Abandoned
- 1996-12-04 IL IL12616196A patent/IL126161A0/xx unknown
- 1996-12-04 DE DE69630055T patent/DE69630055T2/de not_active Expired - Fee Related
- 1996-12-04 CN CN96180207A patent/CN1213970A/zh active Pending
- 1996-12-04 AT AT96942934T patent/ATE249832T1/de not_active IP Right Cessation
- 1996-12-04 PL PL96328948A patent/PL328948A1/xx unknown
- 1996-12-04 AU AU11501/97A patent/AU709181B2/en not_active Ceased
- 1996-12-04 ES ES96942934T patent/ES2206614T3/es not_active Expired - Lifetime
- 1996-12-04 NZ NZ324615A patent/NZ324615A/xx unknown
- 1996-12-04 HU HU9903688A patent/HUP9903688A3/hu unknown
- 1996-12-04 EP EP96942934A patent/EP0946179B1/de not_active Expired - Lifetime
- 1996-12-04 JP JP09532571A patent/JP2000506860A/ja not_active Withdrawn
- 1996-12-04 WO PCT/US1996/019576 patent/WO1997033585A1/en not_active Ceased
- 1996-12-04 BR BR9612552A patent/BR9612552A/pt not_active Application Discontinuation
- 1996-12-04 KR KR1019980707182A patent/KR19990087715A/ko not_active Withdrawn
-
1998
- 1998-09-11 NO NO984197A patent/NO984197L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0946179A1 (de) | 1999-10-06 |
| JP2000506860A (ja) | 2000-06-06 |
| HUP9903688A3 (en) | 2001-12-28 |
| KR19990087715A (ko) | 1999-12-27 |
| EA199800821A1 (ru) | 1999-02-25 |
| BR9612552A (pt) | 1999-07-20 |
| NO984197L (no) | 1998-11-03 |
| AU1150197A (en) | 1997-10-01 |
| CN1213970A (zh) | 1999-04-14 |
| HUP9903688A2 (hu) | 2000-03-28 |
| CZ290498A3 (cs) | 1999-10-13 |
| EP0946179B1 (de) | 2003-09-17 |
| AU709181B2 (en) | 1999-08-26 |
| DE69630055D1 (de) | 2003-10-23 |
| WO1997033585A1 (en) | 1997-09-18 |
| EP0946179A4 (de) | 2000-04-19 |
| NZ324615A (en) | 2000-08-25 |
| DE69630055T2 (de) | 2004-06-03 |
| CA2248741A1 (en) | 1997-09-18 |
| IL126161A0 (en) | 1999-05-09 |
| PL328948A1 (en) | 1999-03-01 |
| TR199801798T2 (xx) | 1998-12-21 |
| EA000768B1 (ru) | 2000-04-24 |
| ES2206614T3 (es) | 2004-05-16 |
| NO984197D0 (no) | 1998-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE266417T1 (de) | Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien | |
| ATE154758T1 (de) | Levobupivacain nützlich zur behandlung von chronischen schmerzen | |
| DE69616376D1 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
| DE69736183D1 (de) | Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen | |
| DE69524679D1 (de) | Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure | |
| DE69636343D1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
| ATE258796T1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
| ATE141505T1 (de) | Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht | |
| ATE145136T1 (de) | Verwendung von ketoconazol und ein retinoid zur behandlung der akne vulgaris | |
| DE68912195D1 (de) | Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis. | |
| DE69713620D1 (de) | Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia | |
| DE69426471D1 (de) | Verwendung von Sulodexid und von Arzneimitteln, die dieses enthalten, zur Behandlung der diabetischen Nephropathie | |
| ATE214272T1 (de) | Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz | |
| ATE249832T1 (de) | Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation | |
| DE69523506D1 (de) | Verwendung eines Enzyms zur Herstellung eines Mittels für die Behandlung und/oder Prophylaxe von Coccidiose | |
| ATE410172T1 (de) | Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes | |
| ATA901396A (de) | Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten | |
| ATE294582T1 (de) | Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs | |
| ATE234613T1 (de) | Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen | |
| ATE236630T1 (de) | Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten | |
| DE69733321D1 (de) | Olanzapine zur behandlung von drogenmissbrauch | |
| ATE225181T1 (de) | Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen | |
| DE69635282D1 (de) | Behandlung der exzessiven aggressivität mit olanzapine | |
| DE59808106D1 (de) | Behandlung der symptome der parkinsonschen krankheit mit einem mittel enthaltend eine dopaminerge substanz und ein lokalanaesthetikum der anilid-gruppe | |
| DE69430807D1 (de) | Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |